Wells Fargo & Company MN Boosts Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Wells Fargo & Company MN boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,928 shares of the company’s stock after purchasing an additional 2,972 shares during the quarter. Wells Fargo & Company MN owned approximately 0.06% of Krystal Biotech worth $2,652,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the third quarter worth approximately $40,000. Avanza Fonder AB purchased a new stake in shares of Krystal Biotech in the 4th quarter valued at approximately $119,000. KBC Group NV raised its holdings in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after purchasing an additional 297 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after purchasing an additional 433 shares during the last quarter. Finally, US Bancorp DE grew its stake in shares of Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Ratings Changes

KRYS has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Citigroup boosted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Chardan Capital increased their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Finally, Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Krystal Biotech has a consensus rating of “Buy” and an average target price of $220.00.

Krystal Biotech Trading Up 2.0 %

Shares of KRYS opened at $169.12 on Friday. The company’s 50 day simple moving average is $176.14 and its 200-day simple moving average is $171.62. The firm has a market cap of $4.89 billion, a PE ratio of 56.56 and a beta of 0.75. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the firm posted $0.30 EPS. Krystal Biotech’s revenue for the quarter was up 116.4% on a year-over-year basis. As a group, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).